The Phase 3 trial conducted by the Lithuanian University of Health Sciences investigates the efficacy of Metformin in conjunction with lifestyle interventions (diet and physical activity) for treating obesity in children and adolescents. Given the rising prevalence of obesity and associated metabolic disorders in pediatric populations, successful outcomes could position Metformin as a first-line treatment option in this demographic, potentially expanding its market beyond adult diabetes management. The competitive landscape includes other anti-obesity medications and lifestyle intervention programs, necessitating a thorough analysis of efficacy, safety, and long-term outcomes to ensure a favorable market entry. Diligence should focus on regulatory pathways and reimbursement strategies for pediatric use.